Molecular Partners to Hold Three Poster Presentations at AACR 2026

Rhea-AI Summary

Molecular Partners (NASDAQ: MOLN) will present three posters at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego. The posters cover DARPin T cell engagers, data-driven tumor-antigen profiling, and a 212Pb Radio-DARPin candidate (MP0712) for SCLC.

Sessions occur April 20 and April 22 with poster numbers 1624, 2691, and 7197 in designated poster sections.

Key Figures

Number of posters: 3 posters AACR 2026 dates: April 17–22, 2026 First poster session start: 4/20/2026 9:00 AM PT +3 more

6 metrics

Number of posters 3 posters Planned presentations at AACR 2026 Annual Meeting

AACR 2026 dates April 17–22, 2026 American Association for Cancer Research Annual Meeting schedule

First poster session start 4/20/2026 9:00 AM PT Immunology T Cell Engagers 1 session

Second poster session start 4/20/2026 2:00 PM PT Application of Bioinformatics to Cancer Biology 3 session

Third poster session start 4/22/2026 9:00 AM PT Targeted Radiopharmaceuticals and Combination Strategies session

Therapeutic isotope 212Pb Radio-DARPin candidate MP0712 for DLL3-targeted radiotherapy

Market Reality Check

Price: $4.34 Vol: Volume 11,644 vs 20-day a...

high vol

$4.34 Last Close

Volume Volume 11,644 vs 20-day average 3,399 (relative volume 3.43) ahead of AACR poster presentations. high

Technical Price 4.34 trades above 200-day MA at 4.03, showing a constructive pre-AACR setup.

Peers on Argus

MOLN gained 2.84% while peers were mixed: INO (+1.82% in sector list, but -1.77%...

1 Up 1 Down

MOLN gained 2.84% while peers were mixed: INO (+1.82% in sector list, but -1.77% in momentum scan), ACTU (+2.59%), GNLX (+0.77%), AVTX (-3.33%). Momentum scanner showed CGEN up and INO down, supporting a stock-specific move rather than a sector-wide rally.

Historical Context

5 past events · Latest: Mar 12 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Full-year 2025 earnings	Negative	-10.4%	Reported 2025 net loss with no revenue but solid cash runway into 2028.
Feb 26	Investor conferences	Neutral	-3.4%	Announced CEO presentations at March 2026 conferences and results date.
Feb 26	Development agreement	Positive	-3.4%	Signed deal with Eckert & Ziegler to support Radio‑DARPin development.
Feb 02	Clinical data update	Positive	+7.5%	Presented first-in-human imaging and dosimetry data for MP0712 at TWC 2026.
Jan 11	Clinical progress	Positive	+1.6%	Outlined MP0712 trial start, pipeline progress, and cash funding into 2028.

Pattern Detected

Recent news often produced modest directional moves, with positive clinical updates tending to see upward reactions and partnership/earnings items sometimes met with weakness.

Recent Company History

Over the last few months, Molecular Partners has focused on advancing its DARPin and Radio‑DARPin pipeline while maintaining a cash runway into 2028. Key milestones included MP0712 entering a U.S. Phase 1/2a trial and first imaging/dosimetry data in patients, plus a development agreement with Eckert & Ziegler. Earnings updates highlighted no 2025 revenue and a net loss, which previously coincided with share price declines. Today’s AACR 2026 poster news fits the ongoing narrative of clinical and platform visibility building around MP0712 and related programs.

Market Pulse Summary

This announcement highlights three AACR 2026 posters featuring Molecular Partners’ DARPin and Radio‑...

Analysis

This announcement highlights three AACR 2026 posters featuring Molecular Partners’ DARPin and Radio‑DARPin oncology programs, including logic‑gated T cell engagers and the 212Pb-based MP0712 candidate. It adds scientific visibility to a pipeline that recently entered Phase 1/2a trials and has upcoming data milestones. Investors may track how AACR findings relate to prior MP0712 imaging results, the broader DARPin platform strategy, and subsequent clinical or regulatory updates through 2026 and beyond.

Key Terms

darPin therapeutics, t cell engager, bioinformatics, radio-darPin, +4 more

8 terms

darPin therapeutics medical

"a novel class of custom-built protein drugs known as DARPin therapeutics"

Darpin therapeutics are medicines built from designed ankyrin repeat proteins — small, engineered proteins crafted to stick to specific molecules involved in disease, much like a custom key fitting a lock. They matter to investors because their compact, stable design can make treatments easier and cheaper to manufacture, allow targeting of multiple disease mechanisms, and may offer faster development paths compared with traditional biologic drugs.

t cell engager medical

"Switch-DARPin T cell engager with CD2 co-stimulation for improved safety"

A T cell engager is an engineered protein drug that physically links a patient’s T cell — the immune system’s attack cell — to a diseased cell so the T cell will recognize and kill it. For investors it matters because clinical trial results, manufacturing success and safety profiles determine whether the therapy becomes a widely adopted, high-value treatment or a costly failure; think of it like a matchmaker that must reliably bring soldiers to the right target without triggering friendly fire.

bioinformatics technical

"Session Category: Bioinformatics / Computational Biology / Systems Biology"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

radio-darPin medical

"Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer"

A radio-darpin is a small, engineered protein that is chemically attached to a tiny radioactive atom and designed to find and stick to a specific molecule on cells, such as a tumor marker. Think of it as a guided homing beacon that either lights up a disease location for imaging or delivers a focused dose of radiation. Investors care because radio-darpins can speed diagnosis, enable more precise treatments, and, if clinically successful, create commercial opportunities or regulatory milestones that drive company value.

radiotherapy medical

"Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer"

Radiotherapy is a medical treatment that uses targeted high-energy radiation to shrink or destroy tumors and control disease, similar to using a focused beam to remove weeds without digging up the whole garden. It matters to investors because approvals, new technologies, clinical trial results, or changes in treatment guidelines can affect demand for equipment, drug combinations, and patient outcomes, which in turn influence revenue and growth prospects for healthcare companies.

immunotherapies medical

"workflow for the development of cancer immunotherapies"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

small cell lung cancer medical

"radiotherapy of small cell lung cancer (SCLC)"

A fast-growing form of lung cancer that tends to spread early to other organs, making it harder to treat than many slower-moving tumors. Investors care because its aggressive nature creates urgent demand for effective drugs, diagnostics and treatments; clinical trial results, regulatory decisions, or new therapies for this disease can quickly reshape a company’s revenue prospects much like a breakthrough product can transform a business in any industry.

dll3 medical

"anti-DLL3 radiotherapy of small cell lung cancer (SCLC)"

DLL3 is a protein found on the surface of some cells that helps control how cells communicate and develop; in certain cancers it becomes much more common on tumor cells than on healthy tissue. Investors watch DLL3 because it can serve as a visible target or marker for drugs and diagnostics—like a unique flag on bad cells—so therapies or tests that successfully exploit DLL3 can drive clinical progress, licensing deals, and potential future revenue.

AI-generated analysis. Not financial advice.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA.

Details of the presentations at AACR 2026:

Logic-gated Switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer
Session Category: Immunology
Session Title: T Cell Engagers 1
Session Start: 4/20/2026 9:00 AM PT
Session End: 4/20/2026 12:00 PM PT
Location: Poster Section 10
Poster Board Number: 16
Poster Number: 1624

Logic-gated Switch-DARPin–based immune cell engagers guided by data-driven tumor-antigen profiling: A computational workflow for the development of cancer immunotherapies
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Session Title: Application of Bioinformatics to Cancer Biology 3
Session Start: 4/20/2026 2:00 PM PT
Session End: 4/20/2026 5:00 PM PT
Location: Poster Section 1
Poster Board Number: 16
Poster Number: 2691

Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC)
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeted Radiopharmaceuticals and Combination Strategies in Cancer Therapy
Session Start: 4/22/2026 9:00 AM PT
Session End: 4/22/2026 12:00 PM PT
Location: Poster Section 17
Poster Board Number: 16
Poster Number: 7197

About Radio-DARPins
Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format.

About DARPin Therapeutics
DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic high affinity and specificity, small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. The Company’s Radio-DARPins enable highly effective and specific delivery of potent radioactive payloads to tumor lesions while sparing healthy tissues. Molecular Partners’ Switch-DARPins allow conditional, tumor-localized immune activation, which enables increased safety and potency for next-generation immune cell engagers. Powered by twenty years of DARPin leadership in the clinic, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs.

About Molecular Partners AG 
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, "anticipate", “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.​

FAQ

What posters will Molecular Partners (MOLN) present at AACR 2026 and when?

Molecular Partners will present three posters at AACR 2026 on April 20 and April 22, 2026. According to the company, topics include Logic-gated Switch-DARPin T cell engagers, computational antigen profiling, and MP0712, a 212Pb Radio-DARPin candidate for SCLC.

Where and when is the Logic-gated Switch-DARPin T cell engager poster (MOLN) shown at AACR 2026?

The Logic-gated Switch-DARPin T cell engager poster is scheduled April 20, 2026, 9:00 AM–12:00 PM PT in Poster Section 10. According to the company, it focuses on CD2 co-stimulation for MSLN and EpCAM co-expressing ovarian cancer.

What is Molecular Partners presenting on computational tumor-antigen profiling at AACR 2026?

Molecular Partners will present a data-driven computational workflow for tumor-antigen profiling on April 20, 2026, 2:00 PM–5:00 PM PT in Poster Section 1. According to the company, the poster covers Switch-DARPin design guided by bioinformatics for cancer immunotherapies.

When and what does MOLN present about MP0712 at AACR 2026?

Molecular Partners will present molecular characteristics of MP0712 on April 22, 2026, 9:00 AM–12:00 PM PT in Poster Section 17. According to the company, MP0712 is a clinical-stage 212Pb-based Radio-DARPin candidate targeting DLL3 for small cell lung cancer.

How can investors or attendees find Molecular Partners' poster numbers at AACR 2026?

Attendees can locate MOLN posters by poster numbers 1624, 2691, and 7197 at AACR 2026. According to the company, each poster lists session category, start/end times, and Poster Section to guide visitors at the San Diego meeting.